Pharming Group N.V. Sponsored ADR

PHAR Healthcare Biotechnology

Pharming Group N.V. Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $376.1 million, up 26.6% from fiscal 2024.

Revenue
+20.9%
EPS
+190.9%
Free cash flow
+0.42%
Total debt
+1.61%

Quarter to September 2026, against a year earlier

12.32 0.02 +0.16%
Market cap
$870.6M
P/E
34.2×
Fwd P/E
0.0×
Dividend yield
—
F-score
5/9
Altman Z
3.88
Beneish M
−2.78
Dividend safety
n/a
Sep '26 Jun '26 Mar '26 Dec '25 Older periods
Piotroski F-Score
7 7 5 5

+8 more TTM periods

ROE
8.73% 3.67% 5.10% 1.14%
ROA
5.00% 2.05% 2.77% 0.63%
ROIC
10.07% 5.50% 8.88% 8.27%
Return on Tangible Assets
10.61% 4.83% 6.50% 1.49%
Average Days of Receivables
70.62 56.75 59.31 53.08
Free Cash Flow per Share
0.49 0.64 0.75 0.78
Free Cash Flow
34.50 34.37 55.72 53.95
Other line items

Show all line items

Columns are period end dates · fundamentals updated 2 Nov 2026